HomeBUSINESS
BUSINESS

Solasia Licenses PTCL Treatment to Columbia Firm in Latin America
(Aug.20.2018)

Tokyo-headquartered oncology specialty firm Solasia Pharma said on August 17 that it has entered into a license agreement with Columbia’s HB Human BioScience on its investigational anticancer agent SP-02 (darinaparsin) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) ...
(LOG IN FOR FULL STORY)